DMK Pharmaceuticals Corporation
DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company's lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergen… Read more
DMK Pharmaceuticals Corporation (DMKPQ) - Total Assets
Latest total assets as of September 2023: $8.96 Million USD
Based on the latest financial reports, DMK Pharmaceuticals Corporation (DMKPQ) holds total assets worth $8.96 Million USD as of September 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
DMK Pharmaceuticals Corporation - Total Assets Trend (2016–2022)
This chart illustrates how DMK Pharmaceuticals Corporation’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
DMK Pharmaceuticals Corporation - Asset Composition Analysis
Current Asset Composition (September 2022)
DMK Pharmaceuticals Corporation's total assets of $8.96 Million consist of 84.8% current assets and 15.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 9.9% |
| Accounts Receivable | $1.09 Million | 9.9% |
| Inventory | $1.24 Million | 11.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2022)
This chart illustrates how DMK Pharmaceuticals Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: DMK Pharmaceuticals Corporation's current assets represent 84.8% of total assets in 2022, an increase from 18.7% in 2016.
- Cash Position: Cash and equivalents constituted 9.9% of total assets in 2022, down from 13.5% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 20.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 11.3% of total assets.
DMK Pharmaceuticals Corporation Competitors by Total Assets
Key competitors of DMK Pharmaceuticals Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
DMK Pharmaceuticals Corporation - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - DMK Pharmaceuticals Corporation generates 0.44x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - DMK Pharmaceuticals Corporation is currently not profitable relative to its asset base.
DMK Pharmaceuticals Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.58 | 1.14 | 3.43 |
| Quick Ratio | 0.54 | 1.01 | 3.27 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-5.59 Million | $ 1.21 Million | $ 32.68 Million |
DMK Pharmaceuticals Corporation - Advanced Valuation Insights
This section examines the relationship between DMK Pharmaceuticals Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.86 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -71.5% |
| Total Assets | $10.93 Million |
| Market Capitalization | $1.01K USD |
Valuation Analysis
Below Book Valuation: The market values DMK Pharmaceuticals Corporation's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: DMK Pharmaceuticals Corporation's assets decreased by 71.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for DMK Pharmaceuticals Corporation (2016–2022)
The table below shows the annual total assets of DMK Pharmaceuticals Corporation from 2016 to 2022.
| Year | Total Assets | Change |
|---|---|---|
| 2022-09-30 | $10.93 Million | -71.46% |
| 2021-09-30 | $38.30 Million | +24.07% |
| 2020-09-30 | $30.87 Million | -35.48% |
| 2019-09-30 | $47.84 Million | -18.02% |
| 2018-09-30 | $58.36 Million | +13.53% |
| 2017-09-30 | $51.40 Million | +36.04% |
| 2016-09-30 | $37.79 Million | -- |